SEC EDGAR · Company announcement
PRAX: 8-K company filing
Filed 8-K for an event or period dated 2026-06-29. Read the company report for its disclosures.
Follow PRAX- Became public
- Jul 2, 2026, 4:30 PM EDT
- Event / period date
- Jun 29, 2026
- Collected
- Nov 9, 2026, 9:07 PM EST
Why this is connected
This filing identifies Praxis Precision Medicines, Inc. as the issuer of the security. The company's SEC identifier connects it to PRAX.
Source evidence
Read the source excerpt or record
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2026 PRAXIS PRECISION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39620 47-5195942 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Praxis Precision Medicines, Inc. 99 High Street , 30th Floor Boston , Massachusetts 02110 (Address of principal executive offices, including zip code) ( 617 ) 300-8460 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ I
Price change after we could observe it
-6.60% PRAX
Adjusted closing prices from Nov 11, 2026 to Nov 12, 2026. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in PRAX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Praxis Precision Medicines PRAX
$1K–$15K · Traded Sep 29, 2026 · disclosed Oct 12, 2026
- Sep 4, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Praxis Precision Medicines PRAX
$1K–$15K · Traded Jul 30, 2026 · disclosed Sep 4, 2026
Traded 7 days before earnings
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.